Virbac stock last at EUR 304.00, up 0.66 percent in Xetra trading

Virbac stock opened at EUR 303.00, reached EUR 304.00 and fell to EUR 301.00 during the September 25 session. The shares were last at EUR 304.00, while the CAC 40 was down 0.16 percent.

Virbac was last at EUR 304.00 on Euronext Paris at 1:22 p.m. CET on September 25, 2026, up 0.66 percent or EUR 2.00 from the prior-session reference of EUR 302.00. Virbac's first-half results and confirmed 2026 targets provided the main dated company backdrop, as Ideal Investisseur reported on September 18, 2026. The shares' five-day performance was down 2.09 percent through September 25, 2026.

The session on September 25, 2026 in figures

Virbac SA (ISIN FR0000031577, Euronext Paris: VIRP) opened at EUR 303.00 and reached a session high of EUR 304.00. The session low was EUR 301.00, producing a EUR 3.00 range between the high and low. Trading volume reached 1,118 shares, compared with 4,422 shares on September 24, 2026 and 4,906 shares on September 21, 2026. The last recorded exchange occurred at 1:22 p.m. CET at EUR 304.00, leaving the shares 0.82 percentage points ahead of the CAC 40's daily move.

Virbac's one-year performance was down 2.58 percent, with a one-year high of EUR 389.50 and low of EUR 297.00. The EUR 304.00 last price stood EUR 85.50 below the one-year high and EUR 7.00 above the one-year low. The daily figures show a move from EUR 303.00 at the opening to EUR 304.00 at the latest recorded exchange. The available session data therefore places the strongest quoted level at EUR 304.00 and the weakest at EUR 301.00.

First-half growth remains the latest company backdrop

Virbac reported first-half 2026 revenue of EUR 768 million, up 7.4 percent at constant exchange rates and scope, according to Ideal Investisseur. The report said companion-animal revenue increased 10.0 percent and livestock revenue increased 6.7 percent. Virbac confirmed its 2026 revenue-growth range of 5.5 percent to 7.5 percent at constant rates and scope. The same report said the adjusted current operating-result margin target was approximately 17 percent.

The company also maintained a cash-generation objective of approximately EUR 80 million, including approximately EUR 125 million of investments. The reported first-half figures followed the September 17, 2026 results release and the September 18, 2026 market reaction. The shares moved from EUR 310.50 on September 18, 2026 to EUR 304.00 on September 25, 2026. That five-session sequence included losses on September 21, September 23 and September 24, followed by a 0.66 percent rise on September 25.

CAC 40 and pharmaceutical shares on September 25, 2026

The CAC 40 was listed as market closed at 8,068.72 points, down 0.16 percent, with the figure updated at 5:13 p.m. CET, as Ideal Investisseur reported. Virbac's 0.66 percent gain exceeded that index move by 0.82 percentage points. Sanofi was reported down 1.17 percent to EUR 71.26 during the Paris session. The pharmaceutical sector was also described as under pressure after Sanofi and eight industry groups called for stronger European pharmaceutical competitiveness.

The SBF 120 was listed at 6,137.92 points, up 0.23 percent on September 25, 2026. Virbac's advance therefore exceeded the broader SBF 120 move by 0.43 percentage points. The shares' recorded EUR 304.00 level was on Euronext Paris rather than a later Tradegate or Lang and Schwarz quotation. The latest quoted Virbac price in this report remains the 1:22 p.m. CET Euronext Paris transaction.